Skip to content

Fabrizio Schifano

University of Hertfordshire

67 papers in the library · 3,116 citations · publishing 2000-2026

Papers

Sort Most recent Most cited

The e-Psychonauts' 'Spiced' World; Assessment of the Synthetic Cannabinoids' Information Available Online.

Current Neuropharmacology 2020 Caroline Zangani, Fabrizio Schifano, Flavia Napoletano et al.

Background: A wide range of novel psychoactive substances (NPS) is regularly searched and discussed online by web-based drug enthusiasts (i.e. the e-psychonauts). Among NPS, the range of synthetic cannabinoids (SC; 'Spice') currently represents a challenge for governments and clinicians. Methods: Using a web crawler (i.e. the NPS.Finder®), the present study aimed at assessing psychonauts'...

The Bridge Between Classical and “Synthetic”/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective

Frontiers in Psychiatry November 20, 2019 Laura Orsolini, Stefania Chiappini, Duccio Papanti et al. 41 citations

The critical spread and dissemination of novel psychoactive substances (NPS), particularly among the most vulnerable youngsters, may pose a further concern about the psychotic trajectories related to the intake of new synthetic drugs. The psychopathological pattern of the "new psychoses" appears to be extremely different from the classical presentation. Therefore, clinicians need more data on...

DOI: 10.3389/fpsyt.2019.00851 (opens in new tab) Addiction Psychopathology Synthetic cannabinoids Perspective graphical +3

New/emerging psychoactive substances and associated psychopathological consequences

Psychological Medicine July 22, 2019 Fabrizio Schifano, Flavia Napoletano, Stefania Chiappini et al. 118 citations

BACKGROUND: The present paper provides an updated review of both the large number of new/novel/emerging psychoactive substances (NPS) and their associated psychopathological consequences. Focus was here given on identification of those NPS being commented in specialised online sources and the related short-/long-term psychopathological and medical ill-health effects. METHODS: NPS have been...

DOI: 10.1017/s0033291719001727 (opens in new tab) Psychopathology Medical prescription Synthetic cannabinoids Mental health +2

Dorsolateral Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: An 18F-FDG PET/CT Case Study

Journal of Psychoactive Drugs February 9, 2019 Lorenzo Moccia, A. Tofani, Marianna Mazza et al. 10 citations

Novel psychoactive substances (NPSs) have currently become a major public health concern because of relatively easy accessibility to these compounds and difficulty in identifying them with routine laboratory techniques. Here, we report the 18F-fluorodeoxyglucose positron emission tomography/computerized tomography (18F-FDG PET/CT) case study of a 23-year-old man who developed a...

DOI: 10.1080/02791072.2019.1578444 (opens in new tab) Dorsolateral prefrontal cortex Positron emission tomography Verbal fluency test Working memory +6

Psychedelic Fauna for Psychonaut Hunters: A Mini-Review

Frontiers in Psychiatry May 22, 2018 Laura Orsolini, Michela Ciccarese, Duccio Papanti et al. 25 citations

Currently different classes of psychoactive substances are easily available for abuse, including several hundred novel psychoactive substances (NPS). Some of these drugs occur naturally in plants and animals or are chemically modified from plant or animal compounds and have been abused by humans over millennia. Recently, the occurrence of a new "drug culture" (e.g., psychonauts) who consume a...

Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder

Journal of Addiction Medicine February 4, 2018 Matteo Caloro, Giuseppa Calabrò, Eleonora de Pisa et al. 9 citations

: Novel psychoactive substance use is a major social concern. Their use may elicit or uncover unpredictably as yet undescribed clinical pictures. We aimed to illustrate a multisubstance use case indistinguishable from paranoid schizophrenia, so to alert clinicians on possibly misdiagnosing substance-induced psychotic disorders. CASE REPORT: We describe a case of a 32-year-old man who started at...

The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review

Frontiers in Psychiatry November 20, 2017 Laura Orsolini, Gabriele Duccio Papanti, Domenico de Berardis et al. 99 citations

Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, cannabis, methylenedioxymethamphetamine (MDMA), psilocybin, mescaline, and psychostimulants. The recent emergence of novel...

4,4′‐Dimethylaminorex (“4,4′‐DMAR”; “Serotoni”) misuse: A Web‐based study

Human Psychopharmacology: Clinical and Experimental May 1, 2017 Barbara Loi, Mire Zloh, Maria Antonietta De Luca et al. 17 citations

BACKGROUND: 4,4'-DMAR (4,4'-dimethylaminorex; "Serotoni") is a potent stimulant drug that has recently been associated with a number of fatalities in Europe. Over the last few years, online communities have emerged as important resources for disseminating levels of technical knowledge on novel psychoactive substances. OBJECTIVE: Analysing the information provided by the fora communities on...

DOI: 10.1002/hup.2575 (opens in new tab) Netnography Harm reduction Stimulant Scientific literature +3

New Psychoactive Substances (NPS) – a Challenge for the Addiction Treatment Services

Pharmacopsychiatry April 25, 2017 Norbert Scherbaum, Fabrizio Schifano, Udo Bonnet 46 citations

Over the last few years, hundreds of new psychoactive substances (NPS) have been identified in Europe. Apart from some herbal compounds, NPS mainly include synthetic cannabinoids and a range of new synthetic stimulants (e. g., cathinones). Synthetic NPS are often developed whilst modifying the basic chemical (e. g., phenethylamine or tryptamine) structure. Although the pharmacology and...

DOI: 10.1055/s-0043-102059 (opens in new tab) Cannabis Addiction Synthetic cannabinoids Designer drug +3

NPS: Medical Consequences Associated with Their Intake.

Current Topics in Behavioral Neurosciences 2017 Fabrizio Schifano, Laura Orsolini, Duccio Papanti et al.

Over the last decade, the 'traditional' drug scene has been supplemented - but not replaced - by the emergence of a range of novel psychoactive substances (NPS), which are either newly created or existing drugs, including medications, now being used in novel ways. By the end of 2014, in excess of 500 NPS had been reported by a large number of countries in the world. Most recent data show,...

DOI: 10.1007/7854_2016_15 (opens in new tab) Full text (opens in new tab) Drug misuse Hallucinogenic drugs Hallucinogens Novel psychoactive substances +4

Evolutionary Considerations on the Emerging Subculture of the E-psychonauts and the Novel Psychoactive Substances: A Comeback to the Shamanism?

Current Neuropharmacology December 2, 2016 Laura Orsolini, Paul St John‐smith, Daniel Mcqueen et al. 28 citations

Indeed, a range of evolutionary mechanisms, such as: optimal foraging, costly signaling, and reproduction at the expense of health may all cooperate to explain the recent spread and diffusion of the NPS market, and this may represent a reason of concern.

DOI: 10.2174/1570159x15666161111114838 (opens in new tab) Shamanism Psychoactive substance Mechanism biology Subculture biology +1

Novel psychoactive substances: the pharmacology of stimulants and hallucinogens

Expert Review of Clinical Pharmacology March 17, 2016 Fabrizio Schifano, Gabriele Duccio Papanti, Laura Orsolini et al. 66 citations

There are increasing levels of concern relating to the rapidly evolving novel psychoactive substances/NPS and web markets' scenarios. The paper aims at providing an overview of the clinical pharmacological issues related to some of the most popular NPS categories, e.g. stimulants and hallucinogens. NPS intake is typically associated with the imbalance of a complex range of neurotransmitter...

DOI: 10.1586/17512433.2016.1167597 (opens in new tab) Hallucinogen Synthetic cannabinoids Pharmacology

Novel psychoactive substances of interest for psychiatry

World Psychiatry February 1, 2016 Fabrizio Schifano, Laura Orsolini, Gabriele Duccio Papanti et al. 319 citations

Novel psychoactive substances include synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor agonists, a range of prescribedmedications, psychoactive plants/herbs, and a large series of performance and image enhancing drugs. Users are typically...

DOI: 10.1002/wps.20174 (opens in new tab) Full text (opens in new tab) Synthetic drugs Mental health Drug testing Neurotransmitters +1

Methoxetamine‐related deaths in the UK: an overview

Human Psychopharmacology: Clinical and Experimental July 1, 2015 Stefania Chiappini, Hugh Claridge, John Corkery et al. 45 citations

OBJECTIVE: The goal of this study is to provide an update on the data given on methoxetamine (MXE)-related fatalities that occurred in 2011-2013, presented at the Second International Conference on Novel Psychoactive Substances. METHODS: Fatalities involving MXE were extracted from the database of the National Programme on Substance Abuse Deaths, which receives information on drug-related...

Olanzapine as the ideal “trip terminator”? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance‐related psychotic symptoms

Human Psychopharmacology: Clinical and Experimental July 1, 2015 Giuseppe Valeriani, Ornella Corazza, Francesco Saverio Bersani et al. 41 citations

OBJECTIVE: The pharmacological self-management of novel psychoactive substance (NPS)-induced psychopathological consequences represents a fast growing phenomenon. This is facilitated by the frequent sharing of NPS intake experiences online and by the ease of access to a range of psychotropic medications from both the online and street market. Olanzapine is anecdotally reported by Web users to...

DOI: 10.1002/hup.2431 (opens in new tab) Olanzapine Schizophrenia object-oriented programming

Venlafaxine as the ‘baby ecstasy’? Literature overview and analysis of web‐based misusers′ experiences

Human Psychopharmacology: Clinical and Experimental July 1, 2015 Giulia Francesconi, Laura Orsolini, Duccio Papanti et al. 22 citations

INTRODUCTION: Venlafaxine is one of the most frequently prescribed antidepressants worldwide, despite its toxicity risk in overdose. Furthermore, the molecule has been recently identified at the EU-wide level as one of the novel psychoactive substances. This paper aims at investigating the potential of misuse, taking into account both the existing literature and the analysis of the misusers'...

Mind navigators of chemicals' experimenters? A web-based description of e-psychonauts.

Cyberpsychology, behavior and social networking May 1, 2015 Laura Orsolini, Gabriele Duccio Papanti, Giulia Francesconi et al. 90 citations

Within online drug fora communities, there are some "educated and informed" users who can somehow provide reliable information on psychoactive compounds and combinations. These users, also called "e-psychonauts," may possess levels of technical knowledge relating to a range of novel psychoactive substances (NPS). The present project aimed at identifying and describing the e-psychonauts'...

Navigating in the Virtual Mind of the Web’: the E-psychonauts’ Profiling

European Psychiatry March 1, 2015 Laura Orsolini, Gabriele Duccio Papanti, Giulia Francesconi et al. 4 citations

In the online drug forum communities there are some 'educated and informed” users who can provide somehow reliable information on psychoactive compounds/combinations. These users, also called 'e-psychonauts”, may possess levels of technical knowledge relating to a range of ”novel psychoactive substances“ (NPS). Our project aimed at identifying and describing what available in terms of the...

Novel psychoactive substances (NPS): clinical and pharmacological issues

Drugs and Alcohol Today February 24, 2015 Fabrizio Schifano 12 citations

Purpose – The purpose of this paper is to provide health professionals with novel psychoactive substances (NPS) clients with up to date information relating to the background, clinical pharmacology and, when possible, clinical management for each of these categories. Design/methodology/approach – The world of NPS is complex and diverse, including a range of different molecules such as:...

DOI: 10.1108/dat-10-2014-0035 (opens in new tab) Synthetic cannabinoids Hallucinogen Pharmacology

“Noids” in a nutshell: everything you (don’t) want to know about synthetic cannabimimetics

Advances in Dual Diagnosis August 12, 2014 Duccio Papanti, Laura Orsolini, Giulia Francesconi et al. 24 citations

Purpose – “Spice” products are synthetic cannabimimetics (SC; also called “synthetic cannabinoids”)-based designer drugs used as a legal alternative to cannabis for their very strong tetrahydrocannabinol (THC)-like effects. The purpose of this paper is to provide an analysis of more recent clinical and pharmacology/toxicology findings relating to SC and describe how they could impact on health,...

DOI: 10.1108/add-02-2014-0006 (opens in new tab) Cannabis Anxiety Synthetic cannabinoids Cannabinoid receptor +3

25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug

BioMed Research International 2014 Francesco Saverio Bersani, Ornella Corazza, Gabriella Albano et al. 98 citations

Introduction. The use of novel psychoactive substances (NPSs) has rapidly increased as well as their online availability. The aim of this paper is to provide a comprehensive review of the nature and the risks associated with 25C-NBOMe, which has recently appeared in the drug market. Methods. A systematic analysis of the scientific literature and a qualitative assessment of online and media...

DOI: 10.1155/2014/734749 (opens in new tab) Full text (opens in new tab) Synthetic drugs Emerging drugs Novel psychoactive substances Research chemicals +22

“Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report

Human Psychopharmacology: Clinical and Experimental July 1, 2013 Duccio Papanti, Fabrizio Schifano, Giulia Botteon et al. 191 citations

OBJECTIVES: The use of synthetic cannabimimetics (SC; "spice" drugs) is increasing, especially among teenagers and young adults. In parallel with this, the number of studies describing intoxication episodes associated with psychotic symptoms in SC users is growing. We present both a systematic review of the related literature and a case report, which seems to highlight the existence of a...

DOI: 10.1002/hup.2312 (opens in new tab) Psychosis Exacerbation Psychopathology Synthetic cannabinoids +1

MDAI (5,6‐methylenedioxy‐2‐aminoindane; 6,7‐dihydro‐5H‐cyclopenta[f][1,3]benzodioxol‐6‐amine; ‘sparkle’; ‘mindy’) toxicity: a brief overview and update

Human Psychopharmacology: Clinical and Experimental July 1, 2013 John Corkery, Simon Elliott, Fabrizio Schifano et al. 52 citations

OBJECTIVES: MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; 'sparkle'; 'mindy') is a psychoactive substance, sold primarily over the Internet and in 'head' shops as a 'legal high'. Synthesised and used as a research chemical in the 1990s, MDAI has structural similarities to MDMA (3,4-methylenedioxy-N-methylamphetamine) and shares its behavioural...

DOI: 10.1002/hup.2298 (opens in new tab) Amine gas treating Stereochemistry Medicinal chemistry Organic chemistry

From “Special K” to “Special M”: The Evolution of the Recreational Use of Ketamine and Methoxetamine

CNS Neuroscience & Therapeutics June 1, 2013 Ornella Corazza, Sulaf Assi, Fabrizio Schifano 147 citations

This article reviews the recreational use of ketamine ("Special K"; KET) and explores the recent diffusion of its new derivative methoxetamine ("Special M"; MXE). The literature search on the nonclinical/recreational use of KET and MXE was carried out in a range of medical databases. Considering the limitations of peer-reviewed information, data were integrated with a qualitative assessment of...

The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): a brief review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry December 3, 2012 John Corkery, Emma Durkin, Simon Elliott et al. 105 citations

5-MeO-DALT (N,N-diallyl-5-methoxytryptamine) is a psychoactive substance, sold primarily over the Internet as a 'research chemical' or 'plant food'. Although details for the synthesis of this tryptamine have been available since 2004, its use as a hallucinogenic drug has been reported only occasionally in on-line user fora. It is controlled in only a few countries world-wide. There is little...